{"id":1068024,"date":"2021-01-27T14:55:14","date_gmt":"2021-01-27T19:55:14","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/intercept-company-statement-on-analyst-note\/"},"modified":"2024-08-18T11:42:03","modified_gmt":"2024-08-18T15:42:03","slug":"intercept-company-statement-on-analyst-note","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/intercept-company-statement-on-analyst-note.php","title":{"rendered":"Intercept Company Statement on Analyst Note"},"content":{"rendered":"<p><![CDATA[NEW YORK, Jan.  27, 2021  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the listing of Intercept\u2019s product on the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) website reached a conclusion regarding the status of a newly identified safety signal (NISS) for Ocaliva\u00ae (obeticholic acid) that the Company believes is incorrect.]]><\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/01\/27\/2165289\/0\/en\/Intercept-Company-Statement-on-Analyst-Note.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Intercept Company Statement on Analyst Note\">Intercept Company Statement on Analyst Note<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Excerpt from: Intercept Company Statement on Analyst Note <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/intercept-company-statement-on-analyst-note.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068024","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068024"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068024"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068024\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}